# GammaTile

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gammatile

- Industry: Medical Devices & Equipment
- Headquarters: Tempe, US
- Website: www.gtmedtech.com/
- Total disclosed funding: $164M
- Latest round: Series E (May 8, 2026)
- Investors on record: 11

## About

GT Medical Technologies, Inc. is a US-based company specializing in GammaTile Therapy, an innovative treatment for malignant intracranial neoplasms that reduces radiation exposure to healthy tissue during cancer treatment. Founded in 2017, GT Medical Technologies, Inc. is based in Tempe, US, and focuses on developing advanced solutions in oncology. In June 2026, GT Medical Technologies, Inc. raised USD 100 million in series E funding led by Viking Global Investors, with participation from MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. GT Medical Technologies specializes in the development and delivery of GammaTile Therapy, a unique treatment solution for patients diagnosed with malignant intracranial neoplasms. This therapy involves placing GammaTile, a surgically targeted radiation therapy system, during tumor resection by neurosurgeons. GammaTile Therapy aims to minimize radiation exposure to healthy tissue, significantly improving patient outcomes by delaying tumor recurrence and potentially extending survival. The company's products primarily serve healthcare providers and patients in North America, focusing on hospitals and oncology centers that provide advanced cancer care.GT Medical Technologies generates revenue through direct sales of its GammaTile Therapy product to healthcare facilities, including hospitals and specialized cancer treatment centers. Transactions typically occur through a direct-to-consumer model, allowing healthcare providers to purchase the GammaTile system and associated training services directly from the company. Pricing structures are tailored based on the specific needs of healthcare providers, ensuring effective implementation of GammaTile Therapy within clinical settings. The company will focus on expanding commercial adoption of GammaTile across hospitals and cancer centers while advancing clinical validation through ongoing trials such as BRIDGES for glioblastoma. Continued investment in clinical data generation and regulatory support will strengthen its positioning as a standard-of-care treatment. Scaling manufacturing and operational infrastructure will support wider market penetration, while positive trial outcomes may enable international expansion and new indications in brain tumor treatment.

## Funding rounds

- Series E, May 8, 2026, $50M — MVM Partners, Gilde Healthcare, Viking Global Investors, Evidity Health Capital, Medical Technology Venture Partners, FemHealth Ventures
- Series D, Jun 10, 2025, $16M — FemHealth Ventures, Warren Point Capital
- Series D, Dec 23, 2024, $37M — MVM Partners, Gilde Healthcare, Accelmed, Evidity Health Capital, Medical Technology Venture Partners
- Series C, Mar 20, 2023, $37M — MVM Partners, Gilde Healthcare, Medical Technology Venture Partners, Bluestone Venture Partners
- Series B, Nov 13, 2020, $15M — MVM Partners, Medical Technology Venture Partners, Bluestone Venture Partners
- Series A, Nov 14, 2018, $5.6M — Medical Technology Venture Partners, Bluestone Venture Partners
- Seed, Dec 29, 2017, $1.9M — Desert Angels, Arizona Tech Investors, Medical Technology Venture Partners

## Investors

- Desert Angels (https://capitalatlas.ai/funds/desert-angels) — Seed
- Arizona Tech Investors (https://capitalatlas.ai/funds/arizona-tech-investors) — Seed
- Medical Technology Venture Partners (https://capitalatlas.ai/funds/medical-technology-venture-partners) — Seed, Series A, Series B, Series C, Series D, Series E
- Bluestone Venture Partners (https://capitalatlas.ai/funds/bluestone-venture-partners) — Series A, Series B, Series C
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series B, Series C, Series D, Series E
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C, Series D, Series E
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series D
- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series D, Series E
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Series D, Series E
- Warren Point Capital (https://capitalatlas.ai/funds/warren-point-capital) — Series D
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series E